Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies, as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients | News & Awards - China Medical University Hospital

Other Hospital CMUH APP icon

About CMUH

News and Award

:::

News and Award/

Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies, as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients

About CMUH

2025/2/17

Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies, as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients

Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies, as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients

Authors : 陳柏谷(Po-Ku Chen)、陳一銘(Yi-Ming Chen)、陳建尉 (Jeremy JW Chen)、陳得源 (Der-Yuan Chen)*

Journal : Rheumatology (Oxford)

Publication Date : 2024

Link : https://pubmed.ncbi.nlm.nih.gov/39447044/

回上頁

Related Articles

Nesfatin-1 Stimulates CCL2-dependent Monocyte Migration And M1 Macrophage Polarization: Implications For Rheumatoid Arthritis Therapy img

Nesfatin-1 Stimulates CCL2-dependent Monocyte Migration And M1 Macrophage Polarization: Implications For Rheumatoid Arthritis Therapy

Assessing the Immune Cell Subset and Genetic Mutations in Patients With Palindromic Rheumatism Seronegative for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide img

Assessing the Immune Cell Subset and Genetic Mutations in Patients With Palindromic Rheumatism Seronegative for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide

Biological ageing: a promising target for prevention and management of rheumatoid arthritis. img

Biological ageing: a promising target for prevention and management of rheumatoid arthritis.

Stay connected with CMUH

youtube

How to get to CMUH the map of hospital

Download

▲

百度搜狗 360搜索金融监管总局：提高保险资金入市比例美财长：美股崩盘原因是DeepSeek 美官员：多国要与美谈判关税问题特朗普下令重审日铁收购提议马布里官宣与中国女歌手结婚

<code id='a2367'></code><style id='61ed4'></style>

<acronym id='e9919'></acronym>

<center id='4097c'><center id='8487f'><tfoot id='d98f4'></tfoot></center><abbr id='a274c'><dir id='52f20'><tfoot id='ff818'></tfoot><noframes id='77e17'>

<optgroup id='511e2'><strike id='ca75b'><sup id='69454'></sup></strike><code id='fbd2a'></code></optgroup>

<b id='23932'><label id='be682'><select id='6f368'><dt id='d2236'><span id='2ee79'></span></dt></select></label></b><u id='bc0f7'></u>

~~<i id='b339d'><strike id='117aa'><tt id='49c2d'><pre id='688ee'></pre></tt></strike></i>~~